Does Rallies show 13F holders for MRK?

Yes. Rallies tracks hedge fund and 13F ownership data for MRK, including fund names, share counts, latest tracked quarter, and position changes when available.

Is MRK research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MRK. It does not provide personalized investment advice.

MRK (Merck) Stock Analysis - Hedge Fund Holdings

Merck (MRK) is a publicly traded Healthcare sector company. As of May 20, 2026, MRK trades at $113.05 with a market cap of $278.00B and a P/E ratio of 31.77. MRK moved -1.07% today. Year to date, MRK is +7.32%; over the trailing twelve months it is +47.92%. Its 52-week range spans $73.31 to $125.14. Analyst consensus is buy with an average price target of $135.61. Rallies surfaces MRK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns MRK stock?

Hedge funds tracked by Rallies that own MRK include Harris Associates, Orbimed Advisors, Pinebridge Investments, Farallon Capital, and Bridgewater Associates. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Merck.

MRK Key Metrics

Key financial metrics for MRK
Metric	Value
Price	$113.05
Market Cap	$278.00B
P/E Ratio	31.77
EPS	$3.57
Dividend Yield	0.85%
52-Week High	$125.14
52-Week Low	$73.31
Volume	5.25M
Avg Volume	0
Revenue (TTM)	$65.77B
Net Income	$8.93B
Gross Margin	73.91%

Top Hedge Funds Holding MRK

Harris Associates holds 12.37M shares of MRK, changed -12.22% as of Mar 31, 2026.
Orbimed Advisors holds 663.40K shares of MRK, changed -20.06% as of Mar 31, 2026.
Pinebridge Investments holds 432.53K shares of MRK, changed -8.76% as of Sep 30, 2025.
Farallon Capital holds 361.00K shares of MRK, changed +0.00% as of Mar 31, 2026.
Bridgewater Associates holds 310.22K shares of MRK, changed -39.64% as of Dec 31, 2025.

Latest MRK News

Merck’s 2024 Adult Pneumonia Vaccine Faces Intensified Competition from Pfizer’s 25-Strain Pediatric Shot — May 20, 2026
Merck Faces Product Liability Trial Over $8.9B Gardasil Sales Peak — May 8, 2026
Merck Animal Health Taps Salesforce Agentforce Life Sciences to Optimize Veterinary Support — May 6, 2026
Merck Finalizes $53-Per-Share Terns Acquisition, Gains FDA-Backed CML Candidate — May 6, 2026
Merck Logs Fourth Straight Beat on KEYTRUDA Growth, Secures Terns Acquisition — May 5, 2026

Recent MRK Insider Trades

Guindo Chirfi sold 10.00K (~$1.21M) on Feb 12, 2026.
Li Dean Y sold 10.23K (~$1.20M) on Feb 10, 2026.
Guindo Chirfi sold 10.00K (~$1.18M) on Feb 9, 2026.

MRK Analyst Consensus

20 analysts cover MRK: 0 strong buy, 13 buy, 7 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $135.61.

Common questions about MRK

Who owns MRK stock?: Hedge funds tracked by Rallies that own MRK include Harris Associates, Orbimed Advisors, Pinebridge Investments, Farallon Capital, and Bridgewater Associates. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Merck.
Does Rallies show 13F holders for MRK?: Yes. Rallies tracks hedge fund and 13F ownership data for MRK, including fund names, share counts, latest tracked quarter, and position changes when available.
Is MRK research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MRK. It does not provide personalized investment advice.